Drugs /

anti-pd-1 antibody

Back to Drugs List

Overview

NCI Definition [1]:
A monoclonal antibody directed against programmed cell death protein 1 (PD-1; PD1; CD279).

Clinical Trials

View Clinical Trials for anti-pd-1 antibody

Anti-pd-1 antibody has been investigated in 11 clinical trials, of which 11 are open and 0 are closed. Of the trials investigating anti-pd-1 antibody, 3 are phase 1 (3 open), 4 are phase 1/phase 2 (4 open), and 4 are phase 2 (4 open).

Deficient DNA Mismatch Repair (dMMR), MLH1 Deficient Expression, and MSH2 Deficient Expression are the most frequent biomarker inclusion criteria for anti-pd-1 antibody clinical trials.

Malignant solid tumor, melanoma, and rectal adenocarcinoma are the most common diseases being investigated in anti-pd-1 antibody clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Anti-Pd-1 Antibody
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating anti-pd-1 antibody and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-pd-1 monoclonal antibody, anti-pd1 antibody, anti-pd1 monoclonal antibody
Drug Target(s) [2]:
PDCD1
NCIT ID [1]:
C128037

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.